Centron pharmaceutical-B (09637.HK): Fully exercise the excess share placement rights, stabilize price actions and stabilize price period ends.

Smart Finance APP news, Pharmaron Pharmaceutical-B (09637.HK) announced that the joint representative (representing itself and the international underwriters) has fully exercised the oversubscription rights as stated in the prospectus on July 24, 2026 (Friday), involving a total of 8.5133 million H shares, accounting for approximately 15% of the total number of shares available for subscription under the global offering before the exercise of oversubscription rights. The oversubscribed shares will be issued and distributed by the company at a price of HK$22.60 per H share. The oversubscribed shares will be used to supplement the oversubscribed allocation in the international offering.